Personalis, Inc.

NASDAQ:PSNL

Medical - Diagnostics & Research

Healthcare
$14.98 +3.44%

+$0.34 today

Market cap
$1.62B
Beta
2.28
P/E (TTM)
-11.0
EPS (TTM)
-$0.92
52W Low $3.84High $12.53

Volume 1.47M

Average 2.31M

PSNL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Personalis, Inc.NASDAQ: PSNL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $2.37M fell 8.3% year over year, in line with the -8.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -8.3% toward the trailing-twelve-month pace of -8.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.37M-3.7% QoQ
Last fiscal yearDec 2025
$10.05M-8.2% YoY
LTMMar 2026
$9.83M-8.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.3%——
1 year-8.2%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
10.05M USD
Year-over-year change
-8.2%
4-year CAGR
+13.7%

Depreciation & Amortization vs competitors

How PSNL compares with its peers on the latest reported figures

  • PSNL's LTM Mar 2026 depreciation & amortization of $9.83M is the smallest of the 10 companies compared; the peer median is $39.23M.
  • Its year-over-year change of -8.1% is the 7th highest of 9, against a peer median of -1.7%.
  • Depreciation & amortization amounts to 15.2% of revenue for PSNL, versus a peer median of 5.9%.
PSNL Competitors Peer median
Depreciation & Amortization for PSNL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRALGRAIL, Inc.LTM Jun 2026$155.37M -1.1%+0.3%94.0%
NTRANatera, Inc.LTM Jun 2026$65.8M +87.5%+37.6%2.4%
NEONeoGenomics, Inc.LTM Jun 2026$65.46M -8.0%-0.8%8.5%
MYGNMyriad Genetics, Inc.LTM Mar 2026$51.8M -13.5%+0.6%6.2%
GHGuardant Health, Inc.LTM Sep 2026$39.23M -2.3%+3.4%3.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$26.88M +15.1%-24.8%5.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$24.2M +0.1%-9.6%7.6%
VCYTVeracyte, Inc.LTM Jun 2026$20.83M -9.4%-6.2%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$12.3M ——3.1%
PSNLPersonalis, Inc.LTM Mar 2026$9.83M -8.1%+6.0%15.2%
Peer median (excluding PSNL) $39.23M-1.7%-0.2%5.9%

Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.23M)(113.32M)(108.3M)(81.28M)(81.27M)
Depreciation & Amortization6.01M8.43M11.3M10.94M10.05M
Deferred Income Tax2.03M0000
Stock-Based Compensation14.38M19.43M14.05M10.69M9.43M
Change in Working Capital(31.14M)10.61M13.48M(2.59M)(10.19M)
Accounts Receivables(12.12M)1.83M(1.09M)9.59M(8.06M)
Inventory29K(2.98M)(1.93M)4.43M(204K)
Accounts Payables(1.46M)3.09M5.18M(8.92M)4.55M
Other Working Capital(17.6M)8.68M11.33M(7.68M)(6.48M)
Other Non-Cash Items3.12M4.61M13.21M17.1M(2.96M)
Operating Cash Flow(70.83M)(70.23M)(56.26M)(45.15M)(74.95M)
Capital Expenditures(11.08M)(49.9M)(10.91M)(1.6M)(4.5M)
Acquisitions (Net)48.99M0(24.01M)00
Purchases of Investments(267.13M)(121.49M)(103.95M)(121.71M)(210.17M)
Sales of Investments218.14M223.92M127.96M88M192.11M
Other Investing Activities(48.99M)024.01M242K0
Investing Cash Flow(60.07M)52.54M13.1M(35.07M)(22.57M)
Debt Repayment3.31M(1.1M)174K(1.13M)585K
Common Stock Issued162.26M03.51M97.82M129.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.13M2.47M7.34M17.98M(189K)
Financing Cash Flow169.7M1.37M11.03M114.67M130.34M
Effect of Forex Changes47K(127K)(16K)(22K)6K
Net Change in Cash38.85M(16.46M)(32.14M)34.43M32.83M
Free Cash Flow(81.91M)(120.13M)(67.17M)(46.75M)(79.45M)

Personalis, Inc.

NASDAQ:PSNL

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.